The invention provides a composition useful to prepare influenza viruses, e. g. , in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.
Cell-Based Systems For Producing Influenza Vaccines
Pamuk Bilsel - Madison WI, US Yoshihiro Kawaoka - Middleton WI, US Gabriele Neumann - Madison WI, US
Assignee:
Flugen, Inc. - Madison WI
International Classification:
C12P 19/34
US Classification:
435 911, 435358, 435325, 4242091
Abstract:
The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines.
Recombinant Influenza Viruses For Vaccines And Gene Therapy
Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles.
Recombinant Influenza Viruses For Vaccines And Gene Therapy
Yoshihiro KAWAOKA - Middleton WI, US Gabriele Neumann - Nanuet NY, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12P 21/02
US Classification:
435 693
Abstract:
A method for producing influenza virus particles for preparation of a vaccine. The method comprises growing reassortant influenza viruses to produce virus particles and recovering the produced virus particles. The reassortant influenza viruses are produced in cultured cells in the absence of helper virus by introducing into the cultured cells expression vectors sufficient to produce genomic vRNA or antigenomic vRNA (cRNA) segments in the cells of reassortant influenza viruses. The method produces a nucleoprotein and an RNA dependent RNA polymerase in the cells so that RNP complexes containing the genomic vRNA segments of the reassortant influenza viruses are formed. The method uses expression vectors containing HA, NA, non-HA and non-NA vRNA segments in which the HA and NA vRNA segments are HA and NA vRNA segments of a viral strain different from a strain that contains all of the non-HA and non-NA vRNA segments.
Youtube
Meine Zukunft: Gabriele Neumann-Beiler zu 50 ...
Unsere Videoserie zum 50. Geburtstag des Nationalparks Bayerischer Wal...
Duration:
55s
Gabriel Neumann, Fiasco Alumni, chats about 6...
Learn how you can support Fiasco Theater at fiascotheater.co...
Duration:
1m 48s
Hatchimals arlarm
Duration:
2m 33s
Neumann University Success - Gabriele Bendist...
Gabriele Bendistis '08 shares how her Neumann education helps her succ...
Duration:
1m 36s
2. Preis: Apothekerin Gabriele Neumann (Karls...
Apotheker aus Aachen, Dsseldorf, Erftstadt und Kln mit Zukunftspr... ...
Duration:
3m 35s
Gruwort von PD Dr. Gabriele Neumann - BISp
Das Bundesinstitut fr Sportwissenschaf... (BISp) hat unter anderem di...
CoroFlu will build on the backbone of FluGens flu vaccine candidate known as M2SR. Based on an invention by UW-Madison virologists and FluGen co-founders Yoshihiro Kawaoka and Gabriele Neumann, M2SR is a self-limiting version of the influenza virus that induces an immune response against the flu.
Yet another tactic is in the works at FluGen, a biotech spinoff that uses technology initially developed in the labs of Yoshihiro Kawaoka and Gabriele Neumann at the University of Wisconsin-Madison. The premise of the companys RedeeFlu vaccineis that it takes a naturally occurring flu virus and mo
Date: Mar 14, 2018
Category: Health
Source: Google
Get ready, some medical experts are predicting the worst flu season in history
Yoshihiro Kawaoka and Dr. Gabriele Neumann and exclusively licensed to FluGen. "Our vaccine, called RedeeFlu, is based on a premise that says, what happens if you take a [naturally occurring] 'wild-type' of flu virus and modify it to infect the human body but don't allow it to replicate and cause i